Japanese Generics Ready Major Launches This Summer
This article was originally published in PharmAsia News
Japanese makers of generic drugs plan major launches of their products this summer, but no branded drug is expected to attract as much attention as Pfizer's Amlodipine (amlodipine besylate) for treating hypertension. A total of 38 companies have clearance from Japan's Health Ministry to sell a generic version of Amlodipine, the country's best-selling drug whose patent protection expired in March. Sawai's version is expected on the market in July. (Click here for more - a subscription may be required
You may also be interested in...
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.